Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 967-972

  Kubota, Tetsuro ^a   Furukawa, Tomoko ^b   Tanino, Hirokazu ^c   Oura, Shoji ^c   Murata, Hiroyuki ^b   Yuasa, Satoko ^b   Morita, Kazue ^b   Ueno, Junji ^b   Kozakai, Rlkatsumi ^b   Yano, Takashi ^b  

^a KEIO UNIVERSITY   (Japan)

^b EIKEN CHEMICAL CO LTD   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anthracycline; Histoculture drug response assay; Human breast cancer; P glycoprotein; THP adriamycin

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; COLLAGEN GEL; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; PIRARUBICIN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 14444280884     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Carter SK: Cancer treatment today and its impact on drug development, with special emphasis on its Phase II clinical trial. J Natl Cancer Inst 57: 235-244, 1976.
2. Vora J, Khaw BA, Narula J and Boroujerdi M: A Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. J Pharm Pharmacol 48: 940-944, 1996.
3. Umezawa H, Takahashi Y, Kinoshita M, Nagasawa H, Masuda T, Ishizuka M, Tatsuta K and Takeuchi T: Tetrahydropyranyl derivatives of daunomycin and doxorubicin. J Antibiot 32: 1082-1084, 1979.
4. Enomoto K, Abe O, Tominaga T, Abe R, lino Y, Koyama H, Fujimoto M and Nomura Y: Clinical study of pirarubicin for breast cancer in Japan. Clinical Study Group of THP for Breast Cancer in Japan. Am J Clin Oncol 13 (Suppl 1): S48-53, 1990.
5. Chevallier B, Mignot L, Delozier T, Morvan F, Ferme C and Herait P: Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer. Am J Clin Oncol 15: 395-398,1992.
6. Stoger H, Bauernhofer T, Schmid M, Ploner F, Moser R, Derstvenscheg E, Steindorfer P, Wilders-Truschnig M, Kuss I and Samonigg H: A phase I/II study of 4′-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. Cancer Chemother Pharmacol 35: 174-178, 1994.
7. Tsuruo T: Mechanism of multidrug resistance and implication for therapy. Jpn J Cancer Res 79: 285-296, 1988.
8. Gerlach JH, Endicotte JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL and Lign V: Homology between P-glycoprotein and a bacterial haemolysin transport protein and a heamolysin transport protein suggests a model for multidrug resistance. Nature 324: 485-489, 1986.
9. Chen, CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB: Internal duplication and homology with bacterial transport protein in the mdr1 (P-glycoprotein) gene from multidrug-resistance human cells. Cell 47: 381-389, 1986.
10. Furukawa T, Kubota T, Murata H, Tanino H, Yuasa S, Morita K, Ueno J, Kozakai K and Yano T: Antitumor spectra of anthracyclines against gastric cancer cells obtained from surgical specimens with reference to P-glycoprotein-expression. (submitted)
11. Freeman AE and Hoffman RM: In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83: 2694-2698, 1986.
12. Vescio RA, Redferm CH, Nelson TJ: In vivo-like drug response of human tumors growing in three-dimensional gel supported primary culture. Proc Natl Acad Sci USA 84: 5029-5033, 1087.
13. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Kase S, Kodaira S, Ishibiki K, Kitajima M and Hoffman RM: High In vitro-in vivo correlation of drug response using sponge-gel supported three-dimensional histoculture and the MTT endpoint. Int J Cancer 51: 489-498, 1992.
14. Furukawa T, Kubota T and Hoffman RM: Clinical application of the histoculture drug response assay. Clin Cancer Res 1: 305-311, 1995.
15. Saikawa Y, Kubota T, Kuo TH, Furukawa T, Kase S, Tanino H, Ishibiki K, Kitajima M and Hofiman RM: Antitumor activity of (2″R)-4′-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo. Anticancer Res 4 (2A): 469-73, 1994.
16. Nguyen HN, Sevin BU, Averette H, Perras J, Untch M, Ramos R, Donato D and Penalver M: Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines. Gynecol Oncol, 45: 164-173, 1992.
17. Tominaga T, Abe O, Enomoto K, Abe R, Iino Y, Koyama H, Fujimoto M and Nomura Y: A randomized controlled study of (2″R)-4′-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan. Biomed Pharmacother 43: 271-278, 1989.
18. Enomoto K, Tominaga T, Abe R, lino Y, Koyama H, Nomura Y, Abe O and Nakazato H: A randomized controlled study of maintenance therapy with (2″R)-4′-O-tetrahydropyranyladriamycin for advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 23: 871-80, 1996. (in Japanese with English abstract)
19. Untch M, Sevin BU, Perras JP, Angioli R, Baibl A, Nguyen HN, Hightower RD and Averette HE: Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro. Gynecol Oncol 47: 172-178, 1992.
20. Nakashima T, Masuda A, Yano G and Maehara Y: Basic and clinical evaluation of the effect of pirarubicin against head and neck cancer -Chemosensitivity test and a comparative study with doxorubicin. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 21: 633-639, 1994. (in Japanese with English abstract)
21. Nakajima O, Imamura Y, Matsumoto A, Koyama Y, Shomura T, Kawamura K and Murata S: Comparative studies on pharmacokinetics between THP and adriamycin in the same patients. Gan to Kagaku Ryoho (Jpn J Cancer Chemother) 13: 261 -270,1986. (in Japanese with English abstract)
22. Saika T, Tsushima T, Nasu Y, Noda M, Akebi N, Kaku S, Takamatsu M, Ohmori H, Uno S and Johsen T: Tissue concentration of intravesically instilled (2″R)-4′-O-tetrahydropyranyl-adriamycin or adriamycin in superficial bladder cancer. Nippon Hinyokika Gakkai Zasshi 84: 1206-1210, 1993. (in Japanese with English abstract)
23. Saika T, Tsushima T, Nasu Y, Akebi N and Ohmori H: Relationship of intracellular concentration and duration of contamination of pirarubicin and adriamycin in human bladder cancer cell lines and human bladder normal mucosa cell line. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 23: 905-909, 1996. (in Japanese with English abstract)
24. Salmon SE, Grogan TM, Miller T, Scheper R and Dalton WS: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81: 696-701, 1989.
25. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R and Silvestrini R: Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 30A: 1002-1007, 1994.
26. Chung HC, Rha SY, Kim JH, Roh JK, Min JS, Lee KS, Kim BS and Lee KB: P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 42: 65-72, 1997.
27. Nagasawa K, Natazuka T, Chihara K, Kitazawa F, Tsumura A, Takara K;, Nomiyama M, Ohnishi N and Yokoyama T: Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother Pharmacol 37: 297-304, 1996.
28. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM and Giaccone G: p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74: 63-68, 1996.